EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of hospital‐administered extended‐release naltrexone on readmission rates for patients with alcohol use disorder

Nathaniel M Singh, Kristin Daniel, Alёna A Balasanova iD

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Nathaniel M Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Naltrexone, Patient Readmission, Delayed-Action Preparations, Alcoholism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Alcohol use disorder (AUD) is a persistent public health concern, contributing significantly to mortality and morbidity. This study aims to evaluate the impact of in‐hospital extended‐release naltrexone (XR‐NTX) administration on alcohol‐related outcomes.

Methods

This retrospective cohort study, conducted at an academic medical centre, included 141 adult patients with AUD who received XR‐NTX between December 2020 and June 2021. Primary and secondary outcomes were assessed 90 days before and after XR‐NTX administration to identify number of alcohol‐related hospitalisations, emergency department (ED) visits and average length of hospital stay. Subgroup analyses assessed outcomes in high hospital utilisers and marginally housed or unhoused populations.

Results

There was a significant decrease in ED visits and length of hospital stay post XR‐NTX and no significant difference in the number of rehospitalisations. Subgroup analysis showed significant reduction in hospital readmissions and ED visits among high hospital utilisers. Our sample was a predominantly middle‐aged, male and white patient population.

Conclusions

In‐hospital initiation of XR‐NTX for AUD was associated with a significant decrease in ED visits and length of hospital stay. While no significant impact on the number of hospitalisations was observed overall, there was a substantial reduction in hospital readmissions and ED visits among high utilisers. Our findings suggest the potential benefits of in‐hospital XR‐NTX, emphasising the need for further research to establish causal relationships, assess cost‐effectiveness and explore effectiveness across diverse patient populations. Effective in‐hospital interventions, such as XR‐NTX, hold promise for improving patient outcomes and reducing the healthcare burden associated with AUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexonePatient ReadmissionDelayed-Action PreparationsAlcoholismLength of StayEmergency Service, HospitalNarcotic AntagonistsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultAged

Stichwörter der Autor:innen

alcohol use disorderhospital readmissionnaltrexonetreatment

Substanzen

NaltrexoneDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Division of Pharmaceutical and Nutrition Care, Nebraska Medicine, Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Alёna A Balasanova

Zitieren

APA

Singh, N. M., Daniel, K., & Balasanova, A. A. (2024). Impact of hospital‐administered extended‐release naltrexone on readmission rates for patients with alcohol use disorder. Internal Medicine Journal. https://doi.org/10.1111/imj.16467

Vancouver

Singh NM, Daniel K, Balasanova AA. Impact of hospital‐administered extended‐release naltrexone on readmission rates for patients with alcohol use disorder. Internal Medicine Journal. 2024. doi:10.1111/imj.16467

BibTeX
@article{Singh2024,
  author = {Singh, Nathaniel M and Daniel, Kristin and Balasanova, Alёna A},
  title = {Impact of hospital‐administered extended‐release naltrexone on readmission rates for patients with alcohol use disorder},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16467}
}
Kostenlos starten →